While the article indirectly mentions MSOS, the focus on Germany's pharmaceutical-oriented cannabis market and the high entry barriers could influence investor perception and interest in MSOS. However, the direct impact on MSOS's stock price in the short term may be neutral, as the ETF's performance is more closely tied to the broader U.S. cannabis market rather than specific international regulatory insights.